Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-α and ribavirin: Results from a randomized, placebo-controlled, double-blind trial

European Journal of Gastroenterology and Hepatology

Volumn 19, Issue 8, 2007, Pages 639-646

  Kronenberger, Bernd ^a   Berg, Thomas ^b   Herrmann, Eva ^c   Hinrichsen, Holger ^d   Gerlach, Tilman ⁱ   Buggisch, Peter ^e   Spengler, Ulrich ^f   Goeser, Tobias ^g   Nasser, Samer ^d   Wursthorn, Karsten ^e   Pape, Gerd R ^h   Hopf, Uwe ^b   Zeuzem, Stefan ^a,c  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

^d UNIVERSITY OF KIEL   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f UNIVERSITY OF BONN   (Germany)

^g UNIVERSITY OF COLOGNE   (Germany)

^h LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

ⁱ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Amantadine; Hepatitis C virus; Quality of life

Indexed keywords

ALPHA INTERFERON; AMANTADINE; INFEX; PLACEBO; RECOMBINANT ALPHA2A INTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALOPECIA; ANGER; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRY SKIN; DYSPNEA; ECZEMA; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEPATITIS C; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; TREATMENT DURATION; WEIGHT REDUCTION; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; AMANTADINE; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; PSYCHOMETRICS; QUALITY OF LIFE; RIBAVIRIN; TREATMENT OUTCOME;

EID: 34447564043     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3281ac20ca     Document Type: Article

References (38)

1. Carithers RL Jr, Sugano D, Bayliss M. Health assessment for chronic HCV infection: results of quality of life. Dig Dis Sci 1996; 41:75S-80S.
2. Forton DM, Thomas HC, Murphy CA, Allsop JM, Foster GR, Main J, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002; 35:433-439.
3. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27:209-212.
4. Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 1999; 30:1299-1301.
5. Wessely S, Pariante C. Fatigue, depression and chronic hepatitis C infection. Psychol Med 2002; 31:1-10.
6. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
7. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
8. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352:1426-1432.
9. Poynard T. Interferon alpha in hepatitis C: a cytokine for reducing fibrosis progression. Eur Cytokine Netw 1997; 8:319-320.
10. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002; 35:704-708.
11. Foster GR. Hepatitis C virus infection: quality of life and side effects of treatment. J Hepatol 1999; 31 (Suppl 1):250-254.
12. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005; 41:790-800.
13. Mulhall BP, Younossi Z. Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C. J Clin Gastroenterol 2005; 39:S23-S27.
14. Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH. The molecular basis of the specific anti-influenza action of amantadine. EMBO J 1985; 4:3021-3024.
15. Wang C, Takeuchi K, Pinto LH, Lamb RA. Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J Virol 1993; 67:5585-5594.
16. Angelico M, Cepparulo M, Angelico F, Francioso S, Barlattani A, Di Candilo F, et al. A randomized controlled trial of amantadine plus interferon-alpha2a vs. interferon-alpha2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha2a monotherapy. Aliment Pharmacol Ther 2004; 19:339-347.
17. Berg T, Kronenberger B, Hinrichsen H, Gerlach T, Buggisch P, Herrmann E, et al. Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial. Hepatology 2003; 37:1359-1367.
18. Brillanti S, Levantesi F, Masi L, Foli M, Bolondi L. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology 2000; 32:630-634.
19. Brillanti S, Foli M, Di Tomaso M, Gramantieri L, Masci C, Bolondi L. Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders. Ital J Gastroenterol Hepatol 1999; 31:130-134.
20. Ferenci P, Formann E, Laferl H, Gschwantler M, Hackl F, Brunner H, et al., for the Austrian Hepatitis Study Group. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40 kDa) plus ribavirin with or without amantadine in treatment-naive patients with chronic hepatitis C genotype 1 infection. J Hepatol 2005; 44:275-282.
21. Gaeta GB, Stornaiuolo G, Stanzione M, Ascione T, Pasquazzi C, Taliani G, et al. Interferon-alpha plus amantadine in chronic hepatitis C resistant to interferon alone: a pilot randomized study. J Viral Hepat 2001; 8:284-286.
22. Helbling B, Stamenic I, Viani F, Gonvers JJ, Dufour JF, Reichen J, et al. Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial. Hepatology 2002; 35:447-454.
23. Khalili M, Denham C, Perrillo R. Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C. Am J Gastroenterol 2000; 95:1284-1289.
24. Mangia A, Ricci GL, Persico M, Minerva N, Carretta V, Bacca D, et al. A randomized controlled trial of pegylated interferon alpha-2a (40 kDa) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C. J Viral Hepat 2005; 12:292-299.
25. Nakamura H, Uyama H, Enomoto H, Kishima Y, Yamamoto M, Yoshida K, et al. The combination therapy of interferon and amantadine hydrochloride for patients with chronic hepatitis C. Hepatogastroenterology 2003; 50:222-226.
26. Teuber G, Berg T, Naumann U, Raedle J, Brinkmann S, Hopf U, Zeuzem S. Randomized, placebo-controlled, double-blind trial with interferon-alpha with and without amantadine sulphate in primary interferon-alpha nonresponders with chronic hepatitis C. J Viral Hepat 2001; 8:276-283.
27. Teuber G, Pascu M, Berg T, Lafrenz M, Pausch J, Kullmann F, et al. Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C. J Hepatol 2003; 39:606-613.
28. Zeuzem S, Teuber G, Naumann U, Berg T, Raedle J, Hartmann S, Hopf U. Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C. Hepatology 2000; 32:835-841.
29. Schwab RS, England AC Jr, Poskanzer DC, Young RR. Amantadine in the treatment of Parkinson's disease. JAMA 1969; 208:1168-1170.
30. Martinez-Martin P, Catalan MJ, Benito-Leon J, Moreno AO, Zamarbide I, Cubo E, et al. Impact of fatigue in Parkinson's disease: the Fatigue Impact Scale for daily use (D-FIS). Qual Life Res 2006; 15:597-606.
31. Schwab RS, England AC Jr. Amantadine HCl (Symmetrel) and its relation to levo-dopa in the treatment of Parkinson's disease. Trans Am Neurol Assoc 1969; 94:85-90.
32. Krupp LB, Coyle PK, Doscher C, Miller A, Cross AH, Jandorf L, et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 1995; 45:1956-1961.
33. Younossi ZM, McCullough AC, Barnes DS, Post A, Ong JP, O'Shea R, et al. Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C. Dig Dis Sci 2005; 50:970-975.
34. McNair DM, Lorr M, Dropplemann LF. Profile of mood states. San Diego: Educational and Industrial Testing Service; 1971.
35. Bullinger M, Heinisch M, Ludwig M, Geier S. Scales for the assessment of health related quality of life: Psychometric analyses of the 'Profile of Mood States' and the 'Psychological General Wellbeing Index' [in German]. Z Differentielle Diagnostische Psychologie 1990; 11:53-61.
36. Gandek B, Ware JE. SF-36 Health survey manual and interpretation guide. Boston: New England Medical Center; The health institute; 1993.
37. Bullinger M, Kirchberger I, von Steinbüchel N. Der Fragebogen The questionnaire everyday life - An approach to measure health related quality of life [in German]. Z Med Psych 1993; 2:121-131.
38. Espadaler Medina JM, Olivella RJ, Ruscadella NJ. Therapeutic effects of amantadine hydrochloride on manifestations of parkinsonism. Rev Esp Otoneurooftalmol Neurocir 1969; 28:236-246.